BIOMAT Database Logo BIOMAT Database Logo

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. 1998

S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.

While engaged in therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopyrido[2, 3-d]pyrimidin-7(8H)-ones as a novel class of potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template. From the lead structure 2, a series of analogues bearing variable substituents at the C-2 position and methyl or ethyl at N-8 was made. Compounds of this series were competitive with ATP and displayed submicromolar to low nanomolar potency against a panel of TKs, including receptor (platelet-derived growth factor, PDGFr; fibroblast growth factor, FGFr; epidermal growth factor, EGFr) and nonreceptor (c-Src) classes. One of the more thoroughly evaluated members was 63 with IC50 values of 0.079 microM (PDGFr), 0.043 microM (bFGFr), 0.044 microM (EGFr), and 0.009 microM (c-Src). In cellular studies, 63 inhibited PDGF-mediated receptor autophosphorylation in a number of cell lines at IC50 values of 0.026-0.002 microM and proliferation of two PDGF-dependent lines at 0.3 microM. It also caused inhibition of soft agar colony formation in three cell lines that overexpress the c-Src TK, with IC50 values of 0.33-1.8 microM. In in vivo studies against a panel of seven xenograft tumor models with known and/or inferred dependence on the EGFr, PDGFr, and c-Src TKs, compound 63 produced a tumor growth delay of 10.6 days against the relatively refractory SK-OV-3 ovarian xenograft and also displayed activity against the HT-29 tumor. In rat oral bioavailability studies, compound 63 plasma concentrations declined in a biexponential manner, and systemic plasma clearance was high relative to liver blood flow. Finally, in rat metabolism studies, HPLC chromatography identified two metabolites of 63, which were proved by mass spectrometry and synthesis to be the primary amine (58) and N-oxide (66). Because of the excellent potency of 63 against selected TKs, in vitro and in vivo studies are underway for this compound in additional tumor models dependent upon PDGFr, FGFr, and c-Src to assess its potential for advancement to clinical trials.

UI MeSH Term Description Entries
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
June 2001, Journal of medicinal chemistry,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications.
November 2019, Molecules (Basel, Switzerland),
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.
April 2005, Bioorganic & medicinal chemistry letters,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
A diversity oriented, microwave assisted synthesis of N-substituted 2-hydro-4-amino-pyrido[2,3-d]pyrimidin-7(8H)-ones.
February 2009, Molecular diversity,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
QSAR of aminopyrido[2,3-d]pyrimidin-7-yl derivatives: anticancer drug design by computed descriptors.
August 2009, Journal of enzyme inhibition and medicinal chemistry,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Synthesis of 2-arylamino substituted 5,6-dihydropyrido[2,3-d]pyrimidine-7(8H)-ones from arylguanidines.
November 2012, Molecular diversity,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
April 2024, European journal of medicinal chemistry,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Synthesis and biological activity of selected 2-substituted 6-(beta-D-ribofuranosyl)oxazolo(5,4-d)pyrimidin-7-ones.
December 1974, Journal of medicinal chemistry,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors.
June 2016, European journal of medicinal chemistry,
S R Klutchko, and J M Hamby, and D H Boschelli, and Z Wu, and A J Kraker, and A M Amar, and B G Hartl, and C Shen, and W D Klohs, and R W Steinkampf, and D L Driscoll, and J M Nelson, and W L Elliott, and B J Roberts, and C L Stoner, and P W Vincent, and D J Dykes, and R L Panek, and G H Lu, and T C Major, and T K Dahring, and H Hallak, and L A Bradford, and H D Showalter, and A M Doherty
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
February 2021, European journal of medicinal chemistry,
Copied contents to your clipboard!